Siren LLC’s Blueprint Medicines BPMC Stock Holding History

Siren LLC’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-726,167	Closed	-$64.3M	–	114
2025 Q1	$64.3M	Buy	+726,167	New	+$70.8M	3.63%	4

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Siren LLC's BPMC Position: Q2 2025 in Review

Siren LLC sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 726,167 shares — an estimated $64.3M sold.

Siren LLC first reported a position in BPMC in Q1 2025 and held it in 1 quarter. The position peaked at $64.3M in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Siren LLC reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Siren LLC sold 726,167 Blueprint Medicines shares in Q2 2025, an estimated $64.3M.
Siren LLC first reported a position in Blueprint Medicines in Q1 2025 and held it in 1 quarter.
Siren LLC's Blueprint Medicines position peaked at $64.3M in Q1 2025.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Siren LLC's 13F filing for Q2 2025, filed 13 Aug 2025.